|
|
Strategic Analysis of Global HIV Diagnostics and Monitoring MarketsPublished by: Frost & Sullivan Published: Feb. 1, 2005 Table of Contents1. Global HIV Diagnostics and Monitoring Markets 1. Overview 1. Introduction 2. Disclaimer 3. Certification 4. Content 5. Research Scope and Methodology 2. Market Dynamics 1. Summary of Findings 2. Market Maturation Process 3. Anticipating the Future 4. Market Segmentation and End Users 5. Customer Priorities 6. Competitive Framework 7. Potential Threat 8. Market Potential 3. Challenges and Strategies 1. Introduction 2. Industry Challenges 3. Challenges and Strategies - 1 4. Challenges and Strategies - 2 5. Challenges and Strategies - 3 6. Challenges and Strategies - 4 7. Challenges and Strategies - 5 8. Challenges and Strategies - 6 4. Total HIV Diagnostics and Monitoring Markets 1. Market Engineering Measurements 2. Total Market Revenue Forecasts 3. Revenues Forecasts by Segments 4. Total Unit Forecasts 5. Unit Forecasts by Segment 6. Revenue Analysis 5. HIV Antibody Screening 1. Introduction 2. Market Engineering Measurements 3. Revenues Forecasts 4. Unit Forecasts 6. HIV Viral Load Monitoring Markets 1. Introduction 2. Market Engineering Measurements 3. Revenues Forecasts 4. Unit Forecasts 7. HIV Genotyping/Phenotyping Markets 1. Introduction 2. Market Engineering Measurements 3. Revenues Forecasts 4. Unit Forecasts 8. HIV CD4/CD8 Monitoring Markets 1. Introduction 2. Market Engineering Measurements 3. Revenues Forecasts 4. Unit Forecasts 9. Competitive Landscape 1. Introduction 2. Competitive Analysis 3. Company Analysis - 1 4. Company Analysis - 2 5. Company Analysis - 3 6. Company Analysis - 4 7. Company Analysis - 5 8. Company Analysis - 6 10. Frost & Sullivan Awards 1. Introduction 2. Frost & Sullivan Awards 3. Technology Innovation Award 4. Technology Excellence Award 5. Patient Value Enhancement Award 11. Decision Support Databases 1. Introduction 2. Global HIV Prevalence 3. Global HIV Prevalence contd. 4. Global HIV Mortality 5. Global HIV Mortality contd. 6. Biotechnology Companies 7. Biotechnology Companies contd. 8. Hospitals 9. Hospitals contd. 10. Hospital Beds 11. Hospital Beds contd. 12. Frost & Sullivan 1. Introduction 2. Healthcare Team 3. Our Capabilities 4. Key Advantages 5. Our Consulting Clients 6. Growth Consulting 7. Growth Consulting Process 8. Growth Consulting Deliverables 9. Growth Partnership Services 10. Growth Partnership Service Platform AbstractDeveloping Countries yet to Embrace HIV Monitoring Tests Human immunodeficiency virus (HIV) as an infection is reaching epidemic proportions across the world. Although the global market for HIV diagnostics and monitoring has successfully produced revolutionary testing technologies, they remain largely unavailable in developing countries and regions such as China, India, and Africa that house a staggering 95 percent of all HIV infected individuals. These countries constantly battle enormous poverty, poor healthcare systems, insufficient resources for prevention and care, and the stigma associated with HIV/AIDS. This situation is worsened by the inability of educational campaigns to reach the sections of society that are most affected by HIV. Without the necessary funds to spend on monitoring and studying possible drug resistance, such countries present a huge challenge to physicians that are unable to perform monitoring tests and consequently market participants are not able to generate revenue from these tests. This report provides a comprehensive analysis of the global HIV diagnostics and monitoring markets, identifying areas with the maximum potential for growth. Detailed revenue forecasts and the worldwide numbers for test units sold help to identify major growth trends in the market. Increasing Drug Resistance Necessitates HIV Monitoring HIV monitoring is becoming essential as a growing number of treated patients develop resistance to many of the earlier antiretrovirals available in the market. "Although compounds with efficacy against multi-drug resistant strains or innovative mechanisms of action are in the clinical development phase, an understanding and monitoring of the resistance plays a crucial role in the treatment," remarks the Frost & Sullivan Industry Manager . With the focus firmly on extending and improving the quality of life of AIDS-affected patients, a greater number of genotyping tests are being conducted, particularly in the United States and Europe. Bulk of Profits Expected from the United States and Europe The HIV diagnostics and monitoring markets in the United States and Europe account for a majority of the revenues generated. "The United States is expected to continue to be a primary profit center for HIV diagnostic test manufacturers despite its low rate of HIV prevalence because the regional pharmacoeconomics support the cost of the tests and monitoring," says Ajmani. Europe is expected to be equally profitable due to the increasing drug resistance in patients and the better reimbursement rates available. Patients in these markets are able to afford expensive screening and genotyping tests and do not mind paying the high prices to enjoy a better quality of life.
|
|
|||
|
About MarketResearch.com
|
||||